Abbott Laboratories stock gains analyst support as dividend streak continues

Abbott Laboratories stock (ISIN US0028241000) is drawing renewed attention after strong second quarter 2026 figures and a fresh dividend declaration, with analysts increasingly supportive of the shares as of September 18, 2026.

Q2 2026 growth underpins Abbott Laboratories stock

In the second quarter of 2026, Abbott Laboratories reported sales of about USD 12.6 billion, an increase of roughly 13 percent compared with the year-ago quarter, giving investors a clearer growth signal in the company’s diversified healthcare portfolio, according to The Motley Fool on September 18, 2026.

Adjusted earnings per share for Abbott Laboratories reached USD 1.31 in the same second quarter of 2026, up from the prior-year period, and exceeded the average analyst estimate of USD 1.28 that had been in place before the release, as shown in data compiled by Yahoo Finance.

The year-on-year improvement in earnings per share corresponds to a positive surprise of about 2.61 percent versus the consensus for the quarter ending June 30, 2026, which reinforces the perception that Abbott Laboratories is executing well on its product pipeline and segment mix, according to the same analyst overview from Yahoo Finance.

Dividend continuity and valuation signal

On September 17, 2026, Abbott Laboratories’ board of directors declared a quarterly common dividend of USD 0.63 per share, marking the company’s 411th consecutive quarterly dividend and underlining its long-standing policy of returning cash to shareholders, as reported by Yahoo Finance.

The cash dividend of USD 0.63 per share is scheduled to be paid on November 16, 2026 to shareholders of record as of October 15, 2026, extending Abbott Laboratories’ status as a long-term income name in the healthcare sector, according to the same report from Yahoo Finance.

Dividend metrics compiled by GuruFocus on September 17, 2026 indicate that Abbott Laboratories’ dividend yield stands at about 2.49 percent with a payout ratio near 46 percent and a three-year dividend growth rate around 7.9 percent, signaling a balance between shareholder distributions and reinvestment.

From a valuation perspective, the same GuruFocus analysis states that Abbott Laboratories’ shares were trading at approximately USD 102.09 as of September 17, 2026, roughly 23.7 percent below an assessed fair value of USD 133.79, suggesting that the stock was modestly undervalued on that metric.

Analyst sentiment and targets for Abbott Laboratories stock

Analyst coverage of Abbott Laboratories remains broad, with 21 buy ratings and one hold rating among 29 analysts, reflecting a predominantly positive stance on the shares as summarized by The Motley Fool.

According to the same analysis from The Motley Fool, recent price target changes include TD Cowen lifting its target to USD 135 from USD 115, Citi increasing its target to USD 125 from USD 112, and Wolfe Research assigning an outperform rating with a USD 130 target, placing the mean-to-high target range between USD 121.33 and USD 143.

These targets stand noticeably above the share levels in the low USD 100 area described in valuation data from GuruFocus, which noted a price of USD 102.09 versus a GF Value of USD 133.79 on September 17, 2026, highlighting an implied upside gap of more than 30 USD per share.

For earnings expectations, consensus data compiled by Yahoo Finance show current estimates for Abbott Laboratories’ 2026 full-year earnings per share around USD 5.52 and for 2027 around USD 6.07, implying expected growth of roughly 9.9 percent in EPS from 2026 to 2027.

Risk backdrop and legal context

Despite the supportive fundamentals, Abbott Laboratories continues to operate against a backdrop of regulatory and legal scrutiny linked to prior safety issues, including a federal case related to manufacturing standards at a facility in Sturgis that has now reached a settlement, as described by Reuters in a story originally published on September 18, 2026.

Regulatory decisions in the broader healthcare space, including product approvals for Abbott Laboratories and peers, continue to shape the operating environment, with recent approval activity summarized by sector media such as BioWorld, which reported on several regulatory decisions affecting multiple pharmaceutical and medical technology companies on September 18, 2026.

Taken together, the settlement of the federal safety suit and the ongoing regulatory approvals illustrate both the risk management aspects and the growth opportunities facing Abbott Laboratories, factors that investors may weigh alongside the company’s earnings trajectory and dividend profile.

Abbott Laboratories stock price and trading context

Recent trading data place Abbott Laboratories stock in the low triple-digit USD range on its primary listing on the New York Stock Exchange, with one valuation snapshot from GuruFocus noting a share price of USD 102.09 and a market capitalization level that aligns with a large-cap healthcare position as of September 17, 2026.

Technical commentary from Traders Union on September 17, 2026 highlighted that Abbott Laboratories shares had moved lower by about 1.57 percent intraday to a price near USD 100.75, trading below several moving average benchmarks and approaching a technical support zone around USD 99.31, underlining a period of short-term pressure even as longer-term fundamentals and analyst views remain constructive.

More news and analyses on Abbott Laboratories stock